If confirmed, anosmia and AD may expand the clinical spectrum of FSHD, and support further an overlap between FSHD1 and FSHD2, highlighting the complex genetic and epigenetic interplay shaping the phenotype. This evidence concerns the gene SMCHD1 and Facioscapulohumeral dystrophy.